Neoadjuvant Chemotherapy And Prognostic Subgroups Defined By Survival Benefit In Patients With Locoregionally Advanced Nasopharyngeal Carcinoma.

X. Ji,Yahua Zhong,Yunfeng Zhou,Fuxiang Zhou,G. Zhang,G. Chen,D. Deng,H. Liu,J. Zhang,Conghua Xie

DOI: https://doi.org/10.1200/jco.2011.29.15_suppl.5536

IF: 45.3

2011-01-01

Journal of Clinical Oncology

Abstract:5536 Background: To evaluate the contribution of neoadjuvant chemotherapy for patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to identify the prognostic subgroups that could benefit the most from neoadjuvant chemotherapy. Methods: From 2004 through 2009, 164 patients with stage II to IVb NPC were treated by radiotherapy alone (RT; n = 74) or chemoradiotherapy (RT/CT; n = 90). All patients received 68-70 Gy to the nasopharynx. Neoadjuvant chemotherapy consisted of 2-4 cycles of cisplatin and 5-fluorouracil, or cisplatin and docetaxel every 3 weeks. Both groups were well-matched for prognostic factors except cancer stage, with more advanced NPC in RT/CT. Results: With a mean follow-up of 34.5 months, the 3-year actuarial rates of overall survival (OS), disease-free survival (DFS), metastasis-free survival and relapse-free survival for RT/CT and RT alone groups were 84.3% v 78.2% (Log-rank P = 0.132), 81.2% v 58.3% (Log-rank P = 0.024), 86.4% v 71.4% (Log-rank P = 0.029) and 94.8% v 79.8% (Log-rank P = 0.114), respectively. Using the Cox model adjusted for prognostic factors, improvement in OS on RT/CT was significant (P = 0.049). Stratification analysis showed that DFS improvement was pronounced in the following prognostic subgroups: stage IV, T3/T4 stage, N2/N3 stage, non-keratinizing carcinoma, youngers, males, smokers, drinkers and patients without family history of cancer. Conclusions: Neoadjuvant chemotherapy improves OS, DFS and MFS for locoregionally advanced NPC, and DFS improvement was pronounced in some prognostic subgroups. Such work could be helpful to guide effective therapy of individuation.